Zacks: Analysts Anticipate Curis, Inc. (CRIS) Will Announce Quarterly Sales of $2.03 Million
Equities analysts expect Curis, Inc. (NASDAQ:CRIS) to report sales of $2.03 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Curis’ earnings, with estimates ranging from $1.90 million to $2.15 million. Curis reported sales of $2.36 million in the same quarter last year, which would suggest a negative year over year growth rate of 14%. The company is expected to issue its next earnings report on Thursday, March 8th.
On average, analysts expect that Curis will report full-year sales of $2.03 million for the current fiscal year, with estimates ranging from $8.50 million to $8.79 million. For the next financial year, analysts forecast that the firm will report sales of $9.69 million per share, with estimates ranging from $8.97 million to $10.40 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that that provide coverage for Curis.
Curis (NASDAQ:CRIS) last announced its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.09) by ($0.02). Curis had a negative net margin of 629.29% and a negative return on equity of 250.58%. The company had revenue of $2.44 million during the quarter, compared to analyst estimates of $2.19 million. During the same quarter last year, the business earned ($0.21) EPS. The firm’s revenue for the quarter was up 38.6% compared to the same quarter last year.
In other Curis news, CEO Ali Ph.D. Fattaey purchased 50,000 shares of the firm’s stock in a transaction dated Wednesday, November 15th. The shares were purchased at an average cost of $1.06 per share, with a total value of $53,000.00. Following the completion of the purchase, the chief executive officer now owns 115,890 shares in the company, valued at approximately $122,843.40. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 4.07% of the company’s stock.
Large investors have recently bought and sold shares of the company. Vanguard Group Inc. lifted its stake in shares of Curis by 2.6% in the second quarter. Vanguard Group Inc. now owns 4,955,068 shares of the biotechnology company’s stock worth $9,365,000 after buying an additional 127,443 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Curis by 62,201.8% in the third quarter. JPMorgan Chase & Co. now owns 2,381,798 shares of the biotechnology company’s stock worth $3,691,000 after buying an additional 2,377,975 shares in the last quarter. State Street Corp lifted its stake in shares of Curis by 10.4% in the second quarter. State Street Corp now owns 1,857,044 shares of the biotechnology company’s stock worth $3,511,000 after buying an additional 175,424 shares in the last quarter. First Eagle Investment Management LLC raised its stake in Curis by 10.4% during the third quarter. First Eagle Investment Management LLC now owns 26,508,672 shares of the biotechnology company’s stock worth $39,498,000 after purchasing an additional 2,500,000 shares during the period. Finally, Goldman Sachs Group Inc. raised its stake in Curis by 1.6% during the second quarter. Goldman Sachs Group Inc. now owns 119,638 shares of the biotechnology company’s stock worth $226,000 after purchasing an additional 1,880 shares during the period. 55.22% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Curis (CRIS) remained flat at $$0.68 during midday trading on Wednesday. 1,032,400 shares of the stock traded hands, compared to its average volume of 1,294,000. Curis has a 12 month low of $0.67 and a 12 month high of $3.22. The firm has a market cap of $113.03, a price-to-earnings ratio of -1.74 and a beta of 1.63. The company has a quick ratio of 5.15, a current ratio of 5.15 and a debt-to-equity ratio of 1.24.
TRADEMARK VIOLATION NOTICE: This news story was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another site, it was copied illegally and reposted in violation of United States & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.americanbankingnews.com/2018/01/10/zacks-analysts-anticipate-curis-inc-cris-will-announce-quarterly-sales-of-2-03-million.html.
Curis Company Profile
Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.